RxDoctor Payments Data

Mark Hines, MD

Interventional Pain Medicine · Mooresville, NCNPI 1790773000

Payments from drug & device makers

What this record shows

Boston Scientific accounts for 94.8% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $3,419 and has fallen 88.0% since, to $409 in 2025.

$6,197in general payments, 2019–2025

Across 76 payments — averaging $81.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$6K
  • Collegium Pharmaceutical, Inc.$116
  • GRT US Holding, Inc.$67
  • Ferring Pharmaceuticals Inc.$36
  • Daiichi Sankyo Inc.$35
  • Shionogi Inc$21
  • plus $48 from 3 others

What the payments were for

  • Travel & lodging$2,48940%
  • Food & beverage$3,70960%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,197 in reported general payments places this provider in the 70th percentile of 45 interventional pain medicine providers in North Carolina.

See all interventional pain medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$211,689
Medicare patients
160
Services billed
2,858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl54$43,426
Xtampza ErOxycodone Myristate84$40,340
Oxycodone Hcl1,303$30,471
Oxymorphone Hcl ErOxymorphone Hcl36$30,357
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen558$22,073
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen367$14,040
Nucynta ErTapentadol Hcl14$13,479
Fentanyl118$13,095
Morphine Sulfate ErMorphine Sulfate211$5,820
Buprenorphine17$4,865
Methadone Hcl160$4,470
Morphine Sulfate136$4,312
Hydromorphone Hcl173$3,337
Lidocaine-PrilocaineLidocaine/Prilocaine17$3,170
Pregabalin106$2,914

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er$116$53,81998 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 45 interventional pain medicine providers in North Carolina.

Other interventional pain medicine in Mooresville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →